HAVCR2 and acute myeloid leukemia: TIM3 (T cell immunoglobulin and mucin domain-3) is an ideal target for selectively killing LSCs but not normal hematopoietic stem cells (HSCs) in most human AML cells, and it was significantly upregulated in the low-risk group, suggesting that patients in the low-risk group might benefit from anti-TIM3 antibodies (Wang Z. et al., 2021).